Market closedNon-fractional
Moderna/MRNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Ticker
MRNA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
5,600
Website
www.modernatx.com
Moderna Metrics
BasicAdvanced
$46B
Market cap
-
P/E ratio
-$15.66
EPS
1.59
Beta
-
Dividend rate
Price and volume
Market cap
$46B
Beta
1.59
Financial strength
Current ratio
4.034
Quick ratio
3.639
Long term debt to equity
9.456
Total debt to equity
9.456
Interest coverage (TTM)
-116.80%
Management effectiveness
Return on assets (TTM)
-15.72%
Return on equity (TTM)
-37.68%
Valuation
Price to revenue (TTM)
8.902
Price to book
3.6
Price to tangible book (TTM)
3.6
Price to free cash flow (TTM)
-12.492
Growth
Revenue change (TTM)
-65.78%
Earnings per share change (TTM)
-234.27%
3-year revenue growth (CAGR)
23.55%
3-year earnings per share growth (CAGR)
118.87%
What the Analysts think about Moderna
Analyst Ratings
Majority rating from 25 analysts.
Moderna Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$167M
-94.06%
Net income
-$1.2B
-641.47%
Profit margin
-703.59%
-9,225.68%
Moderna Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.62
-$9.53
$0.55
-$3.07
-
Expected
-$4.04
-$1.93
-$0.97
-$3.58
-$3.36
Surprise
-10.40%
394.47%
-156.60%
-14.36%
-
Moderna News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
GlobeNewsWire·12 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
PRNewsWire·2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Moderna stock?
Moderna (MRNA) has a market cap of $46B as of July 27, 2024.
What is the P/E ratio for Moderna stock?
The price to earnings (P/E) ratio for Moderna (MRNA) stock is 0 as of July 27, 2024.
Does Moderna stock pay dividends?
No, Moderna (MRNA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Moderna dividend payment date?
Moderna (MRNA) stock does not pay dividends to its shareholders.
What is the beta indicator for Moderna?
Moderna (MRNA) has a beta rating of 1.59. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Moderna stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.